Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
about
The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trialsPI3K inhibitors as new cancer therapeutics: implications for clinical trial designCytokine networking of chondrocyte dedifferentiation in vitro and its implications for cell-based cartilage therapyPotential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disordersToward precision medicine of breast cancerFAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceAkt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myelomaThe phosphoinositide 3-kinase pathway and therapy resistance in cancerComputer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunitiesRapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cellsA phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsTORC2-a new player in genome stabilityOvernutrition, mTOR signaling, and cardiovascular diseases.A new role for an old enemy.Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell linesVS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In VivoMERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy.Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancerp53 and rapamycin are additive.Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non-small-cell Lung CancerBiological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.Nanoproteomic analysis of ischemia-dependent changes in signaling protein phosphorylation in colorectal normal and cancer tissueA liaison between mTOR signaling, ribosome biogenesis and cancerSpontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms.Expression quantitative trait loci for PI3K/AKT pathway.Axl promotes the proliferation, invasion and migration of Wilms' tumor and can be used as a prognostic factor.Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphomaDual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinomaGenomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.Modulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs.Phellinus linteus Mycelium Alleviates Myocardial Ischemia-Reperfusion Injury through Autophagic Regulation.PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.Stem cell state and the epithelial-to-mesenchymal transition: Implications for cancer therapy.Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.Calycosin Enhances Some Chemotherapeutic Drugs Inhibition of Akt Signaling Pathway in Gastric Cells.
P2860
Q26751155-3BB3EA52-43F3-4111-8268-C3C7B3F303D0Q26770489-19D8185C-58D9-47FF-9F4A-0867B0F25262Q26998702-C7E5A3FA-FECB-4060-A719-0A2BF7A33925Q28067037-6C9860BB-A6CB-446C-99EA-F98BF4490EF0Q28073967-0BD9D741-361A-4CB4-8717-6CAC41944A3CQ28077347-03227F4E-F626-4EC0-9F94-94545DF90EF5Q28080599-3C7B8187-2245-497B-BE17-B166BEF8502EQ28081996-AC3BBD39-7C8A-48F3-85CE-CCEC9476B7B3Q28082811-A746BFE0-A0C9-4299-803D-107640465B09Q28397537-A22B60B9-0CBF-40E4-B2B6-4D517D72C712Q33759313-A0121F14-8AF1-4D7B-9773-C552BC2465DFQ33764664-05F13233-7DD3-44F7-9EF3-8A110B96BB62Q34131149-520E10A8-4446-48F9-8F71-A85C586C4A94Q34519316-96F7A8DD-010E-4610-83E6-1D2D6AB20BAEQ35111305-0529258D-374F-445B-B464-58F47727F58CQ35224405-4C9E66E4-8CA7-439A-8815-0B4E29E39224Q35594600-3EF499BF-3B5D-4503-857B-115818244325Q35708311-D533F1A1-9D88-4F9C-908A-BF45929772DFQ35732018-8AE92FF5-57C5-44CB-AD4A-58B662D28C16Q35986673-4A549DF9-51CD-4176-8FDE-2EB90A2EE936Q36140629-48748CF3-7FB1-4CB2-8CC4-B9AD0A434F9EQ36192506-E2B0C641-ED70-4922-A143-5DF578A0D424Q36243104-26BE4DFB-ACFB-4DB4-B40A-D48EC921025FQ36260672-BD765570-0580-4353-BA04-2BC7DA0A4A59Q36443572-840C7EBD-0DB8-43F7-84F6-5627E46FE5D8Q36615429-61EC1D62-2EF2-4C17-B98B-393229711E7CQ37038522-3FD9D6E1-2380-4299-BB98-4CF06CBEF69FQ37582671-3685ABFA-4F71-4CA7-B51C-1AD079CB7959Q37652959-99233EFB-FC4A-4970-861E-55454D056040Q37687313-7C531BFA-E383-401E-97F4-1F966C22F93EQ37702626-78754F41-04F2-44B6-80AB-5B8A7CE7FCA9Q37709086-0BEC2A3A-3A86-4E35-B14B-BB103FC4FE42Q37718224-1CCC490D-C91A-43F7-8A8B-C5C1CF2F3696Q37729599-125CF45F-5C6C-4F1D-A4E1-2F93497E73DCQ37736155-0704D0FF-DBC3-4772-AB29-788DA7ED7C29Q38265574-A389C542-07D3-40D0-BDFB-054438F9A3D2Q38355156-80DA3506-696D-4BE4-8EE3-29D2547646D8Q38364522-5C279778-8A64-45B2-99E9-6D9F192D2B66Q38400600-DEA91494-5B4F-4D2F-A4BA-DAF2C345EA4FQ38709260-5A961B9C-529F-4306-AAB1-16209544556B
P2860
Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Picking the point of inhibitio ...... K/AKT/mTOR pathway inhibitors.
@en
type
label
Picking the point of inhibitio ...... K/AKT/mTOR pathway inhibitors.
@en
prefLabel
Picking the point of inhibitio ...... K/AKT/mTOR pathway inhibitors.
@en
P1476
Picking the point of inhibitio ...... K/AKT/mTOR pathway inhibitors.
@en
P2093
Jordi Rodon
Rodrigo Dienstmann
P304
P356
10.1158/1535-7163.MCT-13-0639
P577
2014-04-18T00:00:00Z